Search
Ionis Pharmaceuticals Inc
IONSAdd to Watchlist
62.040USD
+2.300+3.85%
Close 08-21 16:00（ET）
10.28BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-21The current earnings forecast score of Ionis Pharmaceuticals Inc is 8.00, ranking 168 out of 377 in the Biotechnology & Medical Research industry. The average price target is 87.00, with a high of 110.00 and a low of 46.00.
Analyst Rating
Based on
26
analysts
Buy
Current Rating
88.663
Target Price
+48.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Ionis Pharmaceuticals Inc
IONS
26
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
24
IQVIA Holdings Inc
IQV
24
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Ionis Pharmaceuticals Inc's expected revenue for the next quarter?
Ionis Pharmaceuticals Inc's expected revenue is 182.39M.
What is Ionis Pharmaceuticals Inc's price target?
Analysts forecast that Ionis Pharmaceuticals Inc's price target is USD 87.00, with the highest forecast at USD 110.00 and the lowest forecast at USD 46.00.
How have Ionis Pharmaceuticals IncIONS's recent earnings per share performed?
The market expectation was USD -0.69, while Ionis Pharmaceuticals IncIONS's earnings per share (EPS) for the previous quarter was USD -0.56. EPS for the next quarter is expected at USD -1.21.
What is the analyst rating for Ionis Pharmaceuticals Inc?
Based on the ratings of Ionis Pharmaceuticals Inc's stock from 26 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.